Concepedia

Brian B. Borg

BB

Statistics

Publications

27

Citations

4.2K

H-Index

20

Active since

2006

Affiliations

National Institute of Diabetes and Digestive and Kidney Diseases(Current)

Texas Liver Institute

National Institutes of Health

Washington University in St. Louis

Cedars-Sinai Medical Center

Brian B. Borg is an author at National Institute of Diabetes and Digestive and Kidney Diseases specializing in medicine, liver disease, and hepatology.

ORCID

Publications per year

2006–2023

27

Publications

27

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

, , +8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

, , +12

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao et al. · Gastroenterology · 2019 · 344 citations · Full text

, , +17

Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis

Rohit Loomba, Glen Lutchman, David E. Kleiner et al. · Alimentary Pharmacology & Therapeutics · 2008 · 300 citations · Full text

, , +17

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley et al. · Hepatology · 2020 · 278 citations

, , +17

1–5 of 27